Literature DB >> 22827244

Cell culture-derived influenza vaccines from Vero cells: a new horizon for vaccine production.

Emanuele Montomoli1, Baharak Khadang, Simona Piccirella, Claudia Trombetta, Elisa Mennitto, Ilaria Manini, Valerio Stanzani, Giulia Lapini.   

Abstract

In the 20th century, three influenza pandemics killed approximately 100 million people. The traditional method of influenza vaccine manufacturing is based on using chicken eggs. However, the necessity of the availability of millions of fertile eggs in the event of a pandemic has led research to focus on the development of cell culture-derived vaccines, which offer shorter lead-in times and greater flexibility of production. So far, the cell substrates being evaluated and in use include Vero, Madin-Darby canine kidney, PER.C6 and insect cells. However, Vero cells are the most widely accepted among others. This review introduces briefly the concepts of advanced cell culture-derived influenza vaccine production and highlights the advantages of these vaccines in terms of efficiency, speed and immunogenicity based on the clinical data obtained from different studies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22827244     DOI: 10.1586/erv.12.24

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  20 in total

Review 1.  Systems biology unravels interferon responses to respiratory virus infections.

Authors:  Andrea L Kroeker; Kevin M Coombs
Journal:  World J Biol Chem       Date:  2014-02-26

2.  Shiga toxin glycosphingolipid receptors of Vero-B4 kidney epithelial cells and their membrane microdomain lipid environment.

Authors:  Daniel Steil; Catherine-Louise Schepers; Gottfried Pohlentz; Nadine Legros; Jana Runde; Hans-Ulrich Humpf; Helge Karch; Johannes Müthing
Journal:  J Lipid Res       Date:  2015-10-13       Impact factor: 5.922

3.  Cell culture-derived flu vaccine: Present and future.

Authors:  Alberto Pérez Rubio; Jose María Eiros
Journal:  Hum Vaccin Immunother       Date:  2018-06-28       Impact factor: 3.452

Review 4.  Vaccine approaches conferring cross-protection against influenza viruses.

Authors:  Sai V Vemula; Ekramy E Sayedahmed; Suryaprakash Sambhara; Suresh K Mittal
Journal:  Expert Rev Vaccines       Date:  2017-09-19       Impact factor: 5.217

5.  Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses.

Authors:  Alaina J Mooney; S Mark Tompkins
Journal:  Future Virol       Date:  2013-01-01       Impact factor: 1.831

6.  Comparative glycomics analysis of influenza Hemagglutinin (H5N1) produced in vaccine relevant cell platforms.

Authors:  Yanming An; Joseph A Rininger; Donald L Jarvis; Xianghong Jing; Zhiping Ye; Jared J Aumiller; Maryna Eichelberger; John F Cipollo
Journal:  J Proteome Res       Date:  2013-07-24       Impact factor: 4.466

7.  Production of avian influenza virus vaccine using primary cell cultures generated from host organs.

Authors:  Mustafeez Mujtaba Babar; Muhammad Suleman Riaz; Najam-us-Sahar Sadaf Zaidi; Farhan Afzal; Muhammad Sabir Farooq
Journal:  J Ind Microbiol Biotechnol       Date:  2013-03-21       Impact factor: 3.346

8.  Characterization of reverse genetics-derived cold-adapted master donor virus A/Leningrad/134/17/57 (H2N2) and reassortants with H5N1 surface genes in a mouse model.

Authors:  Irina Isakova-Sivak; Li-Mei Chen; Melissa Bourgeois; Yumiko Matsuoka; J Theo M Voeten; Jacco G M Heldens; Han van den Bosch; Alexander Klimov; Larisa Rudenko; Nancy J Cox; Ruben O Donis
Journal:  Clin Vaccine Immunol       Date:  2014-03-19

9.  Poliovirus-nonsusceptible Vero cell line for the World Health Organization global action plan.

Authors:  Yuko Okemoto-Nakamura; Kenji Someya; Toshiyuki Yamaji; Kyoko Saito; Makoto Takeda; Kentaro Hanada
Journal:  Sci Rep       Date:  2021-03-24       Impact factor: 4.379

10.  Vaccination against influenza with recombinant hemagglutinin expressed by Schizochytrium sp. confers protective immunity.

Authors:  Anne-Cécile V Bayne; David Boltz; Carole Owen; Yelena Betz; Goncalo Maia; Parastoo Azadi; Stephanie Archer-Hartmann; Ross Zirkle; J Casey Lippmeier
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.